Abstract: The present invention is directed to membrane penetrating peptides useful as in vivo, ex vivo and in vitro intracellular delivery devices for compound of interest. More particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.

Abstract: The present invention provides a novel transmembrane protein, which is a nuclear factor of activated T cells (‘NFAT’) receptor, and related compositions and methods.

Abstract: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9, or C5b-9.

Abstract: A promoter comprising the isolated promoter region of the human Thymic Stromal Lymphopoietin (TSLP) gene and functional portions of the promoter region having TSLP promoter activity. The promoters are useful for identifying promoter agonists and antagonists that can be used to prevent or treat allergic conditions and autoimmune diseases.

Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.

Abstract: The present invention provides a novel transmembrane protein, which is a nuclear factor of activated T cells (‘NFAT’) receptor, and related compositions and methods.

Abstract: The present invention relates to agonists, antagonists, and other molecules that specifically bind SIGLEC-6 on mast cells, their use in the treatment of asthma and other SIGLEC-6 mediated diseases or disorders, methods of diagnosing such diseases or disorders, and methods of screening for candidate compounds capable of modulating SIGLEC-6 activity in mast cells. The present invention also relates to the diagnosis and treatment of B-cell related disorders using compounds that bind and/or modulate SIGLEC-6.

Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.

Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.

Abstract: Motifs and patterns are generated by computer and printed on fabric, paper or plastic materials in continuous non-repeating patterns. The data is produced automatically by a random math algorithm, so that each of the printed patterns is similar, but not identical. The layout is arranged in a random manner, so that every part of the print is unique and exclusive. The size, color, motifs as well as the level of similarity or variety of the motifs and any other parameter essential to the design are all managed by the software.

Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.

Abstract: A novel neuroprotectant was identified by microarray analysis that is differentially expressed between the ventricular zone and the cortex of human adult and fetal brain. The secreted protein antagonizes Wnt action in Xenopus embryos. Methods are described for modulating free radical neurotoxicity by contacting cells with the protein, treating neuronal diseases associated with free radical-mediated cell death by administering the protein, determining neuroprotective genomic targets associated with select free radical toxicity pathways by screening with the protein and using the protein to identify other compounds that modulate the biological activity of the secreted protein and the cell machinery that reacts to the secreted protein.

Abstract: Novel nuclear factor of activated T cells (“NFAT”) activating receptor useful for producing agonist and antagonist antibodies that regulate the cellular production and expression of cytokines and cellular receptors. The receptor is a 270 amino acid type I transmembrane protein with a calculated molecular mass of about 30 kD. The receptor has a putative signal peptide at the N-terminal (amino acids 1-42), an Ig-domain (amino acids 43-150) in the extracellular region, a predicted transmembrane domain (amino acids 164-186), and an predicted ITAM motif (amino acids 220-235) in the cytoplasmic region. The receptor activates NFAT, IL-13 and TNF alpha promoter reporter activities.

Abstract: The present invention is directed to membrane penetrating peptides useful as in viv, ex vivo and in vitro intracellular delivery devices for compound of interest. More particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.

Abstract: Mast cell-expressed membrane proteins that are highly expressed in human mast cells and the lungs as compared to brain, heart, kidney, liver, tracheal, and similar tissues. The proteins are transmembrane proteins involved in the regulation of mast cell and lung tissue function, including degranulation of mast cells. The preferred protein is a 187 amino acid transmembrane protein having an intercellular domain comprising amino acids 1 through 82, a transmembrane domain comprising amino acids 83 through 105, and an extracellular domain comprising amino acids 106 through 187 (SEQ ID NO:2).

Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.

Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.

Abstract: Osteopontin is a marker for oligodendrocyte precursor cells. Osteopontin also modulates oligodendrocyte differentiation and central nervous system myelination. Osteopontin induces migration of oligodendrocyte precursors.

Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.

Abstract: The present invention is directed to membrane penetrating peptides useful as in viv, ex vivo and in vitro intracellular delivery devices for compound of interest. More particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.